Close
Almac
Achema middle east

Catalent To Debate Logistics Of Delivery And Transportation Of Cell And Gene Therapies At HPCLC

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Novartis to Lower Innovative Medicines Price in the US

Novartis, which is a leading global innovative medicines company,...

New Agreements with Pharmaceuticals Target Lower U.S. Drug Prices

President Donald Trump on December 19, 2025, said that...
- Advertisement -

Catalent, a global leader in clinical supply services, announced that Ann McMahon, Program Director, Clinical Supply Services and Drug Product Technologies Integration, will participate in a panel session titled “ Cell and Gene Therapy Logistics ” at the upcoming Health and Personal Care Logistics Conference (HPCLC), to be held at the Gwen Hotel, Chicago.

The panel session, on Wednesday, Oct. 30 at 8:30 a.m., comes at a time when there is an increasing focus on individualizing patient care, and panelists will discuss the critical logistics of delivery and transportation as patient care changes; and as cell, gene and biologics therapies constitute an ever-increasing share of treatments. The panelists will also explore future transportation demands.

Ms. McMahon has over 17 years of experience in the pharmaceutical industry. Prior to joining Catalent, she was Manager, New Product Launch at West-Ward Pharmaceuticals, and also Boehringer Ingelheim. She holds a bachelor’s degree in biology/biochemistry from Ohio Northern University, Ada, Ohio; and a master’s degree in clinical pharmacology from the Ohio State University, Columbus, Ohio.

For further information, visit https://www.hpclcnet.org

Latest stories

Related stories

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Novartis to Lower Innovative Medicines Price in the US

Novartis, which is a leading global innovative medicines company,...

New Agreements with Pharmaceuticals Target Lower U.S. Drug Prices

President Donald Trump on December 19, 2025, said that...

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »